Last reviewed · How we verify
Mithramycin A (PLICAMYCIN)
At a glance
| Generic name | PLICAMYCIN |
|---|---|
| Drug class | plicamycin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1970 |
Approved indications
- Malignant tumor of testis
Common side effects
Key clinical trials
- Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases (PHASE1,PHASE2)
- Mithramycin for Lung, Esophagus, and Other Chest Cancers (PHASE2)
- Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mithramycin A CI brief — competitive landscape report
- Mithramycin A updates RSS · CI watch RSS